Aptosyn exisulind: NDA under review

CLPA reported open-label 6-month extension data from 48 patients who participated in the company's Phase II/III study. In the 25 patients who received placebo during the trial and were switched to Aptosyn, there was a statistically significant 50 percent reduction in polyp formation rate. A statistically significant additional reduction of up to 50 percent was also seen in the 23 patients who continued treatment with Aptosyn. ...